{"url_path":"/sec/nthi/8-k/2026-06-23/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1979414/0001829126-26-006773-index.html","accession_number":"0001829126-26-006773","cik":"0001979414","ticker":"NTHI","issuer_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1979414/0001829126-26-006773-index.html","primary_entity_key":"0001979414","primary_entity_name":"NEONC TECHNOLOGIES HOLDINGS, INC."},"word_count":150,"has_tables":true,"body_markdown":"** **\n\n**Item 7.01.**\n**Regulation FD Disclosure.**\n\n \n\nOn June 23, 2026, NeOnc Technologies Holdings,\nInc. (the “Company”) issued a press release announcing that the Department of Health – Abu Dhabi (DOH) has granted Investigational\nNew Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally administered formulation of purified perillyl alcohol\ndesigned for non-invasive nose-to-brain delivery. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form\n8-K.\n\n \n\n*The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.*"}